Drug
AMT2003
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/3)
Active Trials
0(0%)
Terminated
3(100%)
Phase Distribution
Ph phase_2
3
100%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 3 finished
Non-Completion Rate
100.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Terminated(3)
Detailed Status
Terminated3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
terminated3100%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_2
Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003
NCT00405561
terminatedphase_2
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
NCT00332280
terminatedphase_2
Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003
NCT00405873
Clinical Trials (3)
Showing 3 of 3 trials
NCT00405561Phase 2
Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003
NCT00332280Phase 2
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
NCT00405873Phase 2
Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3